HD-OPM Archive
Topics › Infections & vaccines

Metformin and UDCA did not help people who already had long COVID (396-patient trial)

Louis Nervegna · Mar 06, 2026 · ♥ 2 reactions · 0 comments · original Facebook post
Infections & vaccinesInsulin resistance & diabetes
AI summary & key facts

A new trial found neither metformin nor UDCA relieved symptoms in people with established long COVID. Earlier randomized trials showed metformin lowers the risk of developing long COVID when started early in infection, so timing appears to matter.

Previous randomized trials have shown that metformin lowers risk for developing long covid when started soon after infection.

See these past posts:

↪ COVID-OUT: early metformin cut long Covid risk by 42% in a large randomized trial

↪ Metformin cuts long COVID risk in two large randomized trials, COVID-OUT and ACTIV-6

↪ Starting metformin at acute COVID infection lowers long COVID risk in two large RCTs

↪ Metformin cut SARS-CoV-2 viral load 3.6-fold in the COVID-OUT randomized trial

But this latest trial shows no benefit of metformin in patients who already have long covid.

#covidHD #longcovidHD #metforminHD #metformincovidHD #longcovidHD

Research cited

A new clinical study shows that two well-known medications, metformin, which is used for diabetes, and UDCA, which is used for liver disease, do not help treat long COVID symptoms when given after the symptoms have already developed.

Previous research has shown that metformin can reduce the risk of developing long COVID if it is taken early during the acute infection. Therefore, researchers wanted to investigate whether metformin or UDCA could also relieve symptoms in people who already had long COVID.

The study included 396 adults with persistent symptoms after COVID-19. They were randomly assigned to receive either metformin, UDCA, or a placebo for two weeks. The trial was double-blind, meaning that neither the participants nor the researchers knew who received which treatment. After eight weeks, there was no difference between the groups. Those who received the medications did not recover faster and did not experience greater symptom relief than those who received placebo.

The researchers conclude that these medications are not a solution for people who have already developed long COVID. The findings show that there are still no proven effective treatments and that more research is needed to develop targeted therapies, especially those addressing immune system disturbances believed to underlie the condition.

medicalxpress.comDiabetes liver medications covidmedicalxpress.com Paper · Ann Intern Med · 2026Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19acpjournals.org
← newer: One in three people will develop atrial fibrillation; lifestolder: Sugar-sweetened beverages are especially potent drivers of l →